Evaluation of New Biomarker-based Approaches for Improving the Diagnosis of Childhood Tuberculous Meningitis (TBMBIOMARKER)

  • STATUS
    Recruiting
  • End date
    Oct 31, 2024
  • participants needed
    400
  • sponsor
    University of Stellenbosch
Updated on 3 June 2022

Summary

The rapid diagnosis of tuberculosis (TB) in children remains a serious challenge owing to limitations in the existing diagnostic tests. TB meningitis (TBM), an extrapulmonary form of TB, is the most severe manifestation of paediatric TB. TBM results in high morbidity and mortality in children, despite the availability of chemotherapy, mainly due to diagnostic delay. Most tests required for proper TBM diagnosis including analysis of cerebrospinal fluid (CSF) and brain imaging are not available in resource-limited settings e.g., in most of Africa including South Africa. New tests for TBM are urgently needed. The main goal of this proposal is to develop a point-of-care (POC) diagnostic test for TBM, based on CSF and bloodbiomarkers.

Aim 1: Evaluate the diagnostic potentials of 51 host inflammatory biomarkers that the investigators recently identified in CSF and blood samples from children with suspected meningitis in a repository of 100 stored CSF and serum samples using a multiplex platform. After statistical analysis including multi-marker modelling by linear discriminant analysis, random forest, and other modelling techniques, the investigators will select the best combination of up to four biomarkers for incorporation into the prototype diagnostic test (Aim 2).

Aim 2: Incorporate the best performing CSF and serum biomarkers into a novel, patented biosensor-based POC diagnostic test. The investigators will develop a multi-biomarker prototype test for detecting up to 4 biomarkers in serum or CSF.

Aim 3: Evaluate the newly developed POC test on 300 children prospectively. This will be done at the Tygerberg Academic Hospital. The diagnostic yield of the POC test will be compared to the routine diagnostic tests.

Description

IMPORTANCE AND RELEVANCE TO EDCTP2 Despite considerable ongoing efforts in the development of tools to combat tuberculosis (TB), the disease was responsible for approximately 1.6 million deaths, with 10 million people developing the disease worldwide in 2017 (1). An estimated one million children became ill with TB in 2017 (1, 2). Eight countries in Africa or Asia including South Africa, Nigeria, India, China, Indonesia, Philippines, Pakistan and Bangladesh accounted for two-thirds of the world's total burden of TB (1). The TB incidence in South Africa rose from 301 new cases/100,000 in 1990 to 948/100,000 in 2007 (3). The TB burden is worsened by the HIV pandemic, which is rampant in South Africa and other African countries. Tuberculous meningitis (TBM) is the most severe form of TB, occurs mostly during early childhood and has high morbidity and mortality, due to the delayed diagnosis and initiation of appropriate therapy (4). TBM is the most common type of bacterial meningitis in the Western Cape Province of South Africa (5).

New TBM diagnostic tests are needed. Despite ongoing research, early and cost-effective diagnostic tools for TBM are lacking (6). The detection of Mycobacterium tuberculosis (Mtb) in cerebrospinal fluid (CSF) is the gold standard for diagnosing TBM. Unfortunately the sensitivity of both smear microscopy and culture for TBM is low (7, 8). Depending on the reference standard employed, the sensitivity of the GeneXpert test (Cepheid Inc, USA) for TBM is approximately 50-60%, and improved to 72% when centrifuged CSF was used in one study (9). In a more recently published study conducted on HIV positive adults, however, the GeneXpert performed with a sensitivity of 43% or 45%, compared to 43% or 45% for culture and 70% or 95% for the GeneXpert Ultra, depending on which of the two reference standards were used (10). Despite the relatively high roll-out of the GeneXpert test across South Africa, the test is currently mostly offered at centralised laboratories. The availability of the test in other African countries is limited. The diagnosis of TB relies on the poorly sensitive symptom screening and smear microscopy, especially at rural health centres. Mtb culture facilities are often only available at referral level laboratories and results might take up to 42 days. The need for multiple health care visits leads to loss of follow-up and delayed diagnosis, fuelling the spread of TB and advanced lung damage. In the case of TBM in particular, proper diagnosis is only made upon admission in a tertiary level referral center. In routine clinical practice, diagnosis is mostly based on a combination of clinical findings, multiple laboratory tests on the CSF, imaging findings and the exclusion of common differential diagnoses (11). Most of these techniques are unavailable in many high-burden, but resource-constrained settings in most of sub-Saharan Africa. Children seen at primary and secondary healthcare facilities often have multiple missed opportunities, up to six visits, before eventual diagnosis of TBM is made in a relatively well-resourced setting in South Africa (12). Findings from the CSF can be highly variable (13). Recently, international experts have proposed new uniform case definitions that should be employed in future research (14, 15) to replace the many different definitions in the literature (7, 8, 13, 16, 17). New tests are therefore urgently needed for the diagnosis of TBM.

Point-of-care (POC) or bedside diagnostic tools are needed in Sub-Saharan Africa. Any new tests for TBM must be rapid, easy to perform at the POC or bedside, and suitable for use in resource-poor settings in African countries. Such tests should, therefore, preferably not use laboratory instruments that require specialists to operate. They should use portable batteryor solar-operated hand-held devices, suitable for use by nurses and community health workers (18). Diagnostics based on the human immune response may provide important additions, which are easily converted to POC or bedside diagnostic tools.

Host CSF protein signatures as diagnostic candidates for TBM. The investigators investigated the potential of host markers detected in CSF samples from children suspected of having TBM as diagnostic candidates for TBM (19). The investigators evaluated the levels of the host biomarkers present in a standard BioPlex 27plex multiplex cytokine kit (Bio Rad Laboratories) and other protein biomarkers in CSF and serum samples. An unsupervised hierarchical clustering and principal component analysis, using the Glucore Omics explorer, revealed significant clustering of patients with TBM by the biomarkers detected in the CSF.

A 3-marker host protein biosignature comprising vascular endothelial growth factor (VEGF), interleukin (IL)-13 and the antibacterial peptide cathelicidin, LL-37, showed potential as a diagnostic biosignature for TBM (international patent application: PCT/IB2015/052751) (19), diagnosing TBM with an area under the receiver operator characteristics curve (AUC) of 0.91, with sensitivity of 52%, but with good specificity of 95%. Since the publication of this biosignature, the investigators have evaluated the diagnostic potential of >70 host biomarkers in serum and plasma samples from adults suspected of having active pulmonary TB in 5 different African countries (South Africa, Namibia, Malawi, Uganda and Ethiopia) in an EDCTP-funded trial (AE-TBC). The investigators identified, patented (PCT/IB2015/051435 and PCT/IB2017/052142), and published 6- and 7-marker protein biosignatures with strong diagnostic potential for TB (20, 21).

In a more recent study (South African Provisional Patent application; Manyelo et al 2019, in press), the investigators hypothesized that at least some of the host biomarkers comprising our adult protein biosignatures may be useful for TBM diagnostics. Funded by the South African Technology Innovation Agency (PI: Chegou), the investigators prospectively enrolled a new cohort of children suspected of having TBM at the Tygerberg Academic Hospital, Western Cape, and determined the concentrations of 66 host biomarkers, in CSF samples from these children. The investigators also included the 3 biomarkers that comprised our previous CSF biosignature for TBM (VEGF, IL-13 and cathelicidin LL-37) (19) for validation purposes in this new study; a total of 69 host protein biomarkers.

With the exception of VEGF (AUC of 0.81), the accuracy of the individual markers in the previous 3-marker signature was poor (AUCs of 0.58 and 0.55, respectively, for IL-13 and LL-37) but when used in combination the discrimination between TBM and no-TBM by the 3-marker model was confirmed [AUC of 0.67 (95% CI: 0.52-0.83); sensitivity of 75% and specificity of 65%]. Forty-seven of the additional markers showed significant differences between the TBM and no TBM groups (Mann Whitney U test), with 28 showing strong diagnostic potential, even as individual markers (AUC ≥ 0.80). These markers include interferon (IFN)-γ, CCL18(MIP-4), CXCL9, CCL1, CCL5(RANTES), IL-6, tumour necrosis factor (TNF)-α, myeloperoxidase (MPO), matrix metalloproteinase 9 (MMP), MMP-8, complement C2 (CC2), IL-10, total plasminogen activator inhibitor 1 (PAI-1), CXCL8, IL-1β, alpha-2-antitrypsin(A1AT), CXCL10, granulocyte colony stimulating factor (G-CSF), CC4, CC4b, granulocyte-macrophage colony stimulating factor (GM-CSF), platelet-derived growth factor (PDGF)-AB/BB, apolipoprotein A1 (apoA1), mannose-binding lectin (MBL), ferritin, CC5a, serum amyloid P (SAP), and CC5.

Combinations of these biomarkers were investigated and using Linear Discriminant Analysis (LDA) models. A 4-marker CSF biosignature comprising soluble intracellular adhesion molecule (sICAM)-1, MPO, CXCL8 and IFN-γ diagnosed TBM with an AUC of 0.97 (95% CI: 0.92-1.00), with a sensitivity of 87% (20/23) and specificity of 95.8% (23/24). After leave-one-out cross validation, there was no change in the sensitivity and specificity of the 4-marker biosignature. Further optimization of the 4-marker biosignature by the selection of better cut-off values resulted in a sensitivity and specificity of 96% and 96%, respectively.

As VEGF performed well in single-marker analyses (19), the investigators evaluated the potential accuracy of other biosignatures that included VEGF. A 3-marker model comprising VEGF, IFN-γ and MPO discriminated with high accuracy between the children with and without TBM. In leave-one-out cross validation and optimizations of best cut-off values, the sensitivity and specificity of the 3-marker VEGF-based signature were 92% and 100%, respectively.

Serum host protein signatures as diagnostic candidates for TBM. All 69 host markers investigated in CSF samples were also investigated on serum samples using the Luminex multiplex platform. The median serum levels of 17 analytes [sVCAM1, CCL2, IL-4, TNF-α, CCL4, adipsin, SAP, CC5, CFH, G-CSF, IL-10, Apo-CIII, IL-17A, PAI-1(total), PDGF AB/BB, MBL and NCAM1] were significantly different (p<0.05; Mann Whitney U test) between children with and without TBM. When the diagnostic potential of individual serum biomarkers was assessed by ROC curve analysis, 13 of the markers had promising AUC ≥ 0.70. LDA demonstrated that optimal diagnosis of TBM was achieved using 3 markers. The most accurate 3-marker serum biosignature for the diagnosis of TBM [adipsin (complement factor D), Ab42 and IL-10] diagnosed TBM with an AUC of 0.84 (95% CI: 0.73-0.96), a sensitivity of 82.6% (19/23) and specificity of 75% (18/24). In leave-one-out cross validation, the sensitivity remained 82.6% (19/23) with the specificity decreasing to 70.3% (17/24). Further optimisation of the biosignature by selection of better cut-off values resulted in an improved sensitivity and specificity of 83% and 83%, respectively.

Biosensor-based diagnostic platform. The best performing CSF and serum biomarkers for TBM will be incorporated into a novel POC diagnostic platform to be developed at the Engineering Faculty, SU. The investigators have developed a prototype piezoelectric sensor using ZnO nanowires, as well as a resistive sensing element based on an electrospun nanofiber mesh (22). The device successfully detected E. coli (23). The investigators have also used this technique to detect small quantities of the protein LC3, a biomarker for autophagy activity and as part of a recent masters project, the platform was capable of detecting IFN-γ, a key TB biomarker in fg/ml ranges, thus demonstrating its potential high sensitivity.

We will use a similar approach to develop a multi-biomarker based prototype test that is capable of detecting up to 4 biomarkers in serum or CSF, and prospectively evaluate the test on 300 newly recruited children with suspected TBM (Aim 3).

OVERALL OBJECTIVE The main objective is to validate previously identified host serum and CSF biomarkers and to develop a biosensor-based POC test for the diagnosis of TBM, based on these biomarkers.

The investigators propose to identify a panel of correlated biomarkers that showed potential in previous studies. This will be done to identify biomarkers which can be substituted with each other as the transition from a laboratory-based technological platform such as Luminex to a POC test using a biosensor-based technology is likely to be faced by the loss of some of the markers due to technical reasons or due to unavailability of some of the markers due to antibody ownership or cost issues. Highly correlated markers can then substitute such markers. The investigators will test which set of biomarkers works best in the POC diagnostic test platform. Finally, the investigators will evaluate the prototype test prospectively in a new cohort of 300 study participants with suspected TBM as described below.

The prototype test will be based on the best biosignature of CSF or serum biomarkers, depending on which performs best. However, developing the test based on serum biomarkers may be advantageous as CSF samples are difficult to collect. Furthermore, a test based on serum biomarkers may be easily converted to a fingerprick based test, which will be much easier to implement in resource-constrained settings. The investigators are currently evaluating a fingerprick screening test for adult TB based on host biomarkers discovered and validated in serum samples as part of an EDCTP2-funded consortium (www.screen-tb.eu).

References

  1. World Health Organisation. Global tuberculosis report 2018.
  2. World Health Organisation. Tuberculosis Fact Sheet. 2018.
  3. World Health Organisation. Global Tuberculosis Control; Epidemiology, Strategy and Financing. World Health Organisation Report 2009.
  4. Schoeman J, Wait J, Burger M, van Zyl F, Fertig G, van Rensburg AJ, et al. Long-term follow up of childhood tuberculous meningitis. Developmental medicine and child neurology. 2002;44(8):522-6. https://doi.org/10.1111/j.1469-8749.2002.tb00323.x
  5. Donald PR, Cotton MF, Hendricks MK, Schaaf HS, de Villiers JN, Willemse TE. Pediatric meningitis in the Western Cape Province of South Africa. Journal of tropical pediatrics. 1996;42(5):256-61. doi: 10.1093/tropej/42.5.256.
  6. Thwaites GE, van Toorn R, Schoeman J. Tuberculous meningitis: more questions, still too few answers. The Lancet Neurology. 2013;12(10):999-1010. doi: 10.1016/S1474-4422(13)70168-6
  7. Hosoglu S, Geyik MF, Balik I, Aygen B, Erol S, Aygencel TG, et al. Predictors of outcome in patients with tuberculous meningitis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2002;6(1):64-70. PMID: 11931403
  8. van Well GT, Paes BF, Terwee CB, Springer P, Roord JJ, Donald PR, et al. Twenty years of pediatric tuberculous meningitis: a retrospective cohort study in the western cape of South Africa. Pediatrics. 2009;123(1):e1-8. doi: 10.1542/peds.2008-1353
  9. Bahr NC, Marais S, Caws M, van Crevel R, Wilkinson RJ, Tyagi JS, et al. GeneXpert MTB/Rif to Diagnose Tuberculous Meningitis: Perhaps the First Test but not the Last. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;62(9):1133-5. doi: 10.1093/cid/ciw083
  10. Bahr NC, Nuwagira E, Evans EE, Cresswell FV, Bystrom PV, Byamukama A, et al. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study. The Lancet Infectious diseases. 2018;18(1):68-75. doi: 10.1016/S1473-3099(17)30474-7.
  11. Marais SW, Wilkinson R J. The diagnosis and medical management of tuberculous meningitis in adults. South African Medical Journal. 2014;104(12). DOI:10.7196/SAMJ.9060
  12. Solomons R, Grantham M, Marais BJ, van Toorn R. IMCI indicators of childhood TBM at primary health care level in the Western Cape Province of South Africa. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2016;20(10):1309-13. DOI: 10.5588/ijtld.16.0062
  13. Bhigjee AI, Padayachee R, Paruk H, Hallwirth-Pillay KD, Marais S, Connoly C. Diagnosis of tuberculous meningitis: clinical and laboratory parameters. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2007;11(4):348-54. DOI: 10.1016/j.ijid.2006.07.007
  14. Marais S, Thwaites G, Schoeman JF, Torok ME, Misra UK, Prasad K, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. The Lancet Infectious diseases. 2010;10(11):803-12. doi: 10.1016/S1473-3099(10)70138-9
  15. Goenka A, Jeena PM, Mlisana K, Solomon T, Spicer K, Stephenson R, et al. Rapid Accurate Identification of Tuberculous Meningitis Among South African Children Using a Novel Clinical Decision Tool. The Pediatric infectious disease journal. 2018;37(3):229-34. DOI: 10.1097/INF.0000000000001726
  16. Andronikou S, Wilmshurst J, Hatherill M, VanToorn R. Distribution of brain infarction in children with tuberculous meningitis and correlation with outcome score at 6 months. Pediatric radiology. 2006;36(12):1289-94. DOI: 10.1007/s00247-006-0319-7
  17. Saitoh A, Pong A, Waecker NJ, Jr., Leake JA, Nespeca MP, Bradley JS. Prediction of neurologic sequelae in childhood tuberculous meningitis: a review of 20 cases and proposal of a novel scoring system. The Pediatric infectious disease journal. 2005;24(3):207-12. DOI: 10.1097/01.inf.0000154321.61866.2d
  18. World Health Organisation. Meeting Report: High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. Geneva: World Health Organisation; 2014 28-29 April 2014.
  19. Visser DH, Solomons RS, Ronacher K, van Well GT, Heymans MW, Walzl G, et al. Host immune response to tuberculous meningitis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015;60(2):177-87. doi: 10.1093/cid/ciu781
  20. Chegou NN, Sutherland JS, Malherbe S, Crampin AC, Corstjens PL, Geluk A, et al. Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB. Thorax. 2016. Thorax. 2016;71(9):785-94. doi: 10.1136/thoraxjnl-2015-207999
  21. Jacobs R, Malherbe S, Loxton AG, Stanley K, van der Spuy G, Walzl G, et al. Identification of novel host biomarkers in plasma as candidates for the immunodiagnosis of tuberculosis disease and monitoring of tuberculosis treatment response. Oncotarget. 2016;7(36):57581-92. doi: 10.18632/oncotarget.11420
  22. Neveling DP, van den Heever TS, Perold WJ, Dicks LMT. A nanoforce ZnO nanowire-array biosensor for the detection andquantification of immunoglobulins. Sensors and Actuators
  23. 2014;203:102-10. https://doi.org/10.1016/j.snb.2014.06.076
  24. Maas MB, Maybery GHC, Perold WJ, Neveling DP, Dicks LMT. Borosilicate Glass Fiber-Optic Biosensor for the Detection of Escherichia coli. Current microbiology. 2018;75(2):150-5. doi: 10.1007/s00284-017-1359-y.
  25. Corstjens PL, Tjon Kon Fat EM, de Dood CJ, van der Ploeg-van Schip JJ, Franken KL, Chegou NN, et al. Multi-center evaluation of a user-friendly lateral flow assay to determine IP-10 and CCL4 levels in blood of TB and non-TB cases in Africa. Clinical biochemistry. 2016;49(1-2):22-31. doi: 10.1016/j.clinbiochem.2015.08.013
  26. Sutherland JS, Mendy J, Gindeh A, Walzl G, Togun T, Owolabi O, et al. Use of lateral flow assays to determine IP-10 and CCL4 levels in pleural effusions and whole blood for TB diagnosis. Tuberculosis (Edinburgh, Scotland). 2016;96:31-6. doi: 10.1016/j.tube.2015.10.011.
  27. Marais BJ, Heemskerk AD, Marais SS, van Crevel R, Rohlwink U, Caws M, et al. Standardized Methods for Enhanced Quality and Comparability of Tuberculous Meningitis Studies. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017;64(4):501-9. doi: 10.1093/cid/ciw757.
  28. Kashyap RS, Dobos KM, Belisle JT, Purohit HJ, Chandak NH, Taori GM, et al. Demonstration of components of antigen 85 complex in cerebrospinal fluid of tuberculous meningitis patients. Clinical and diagnostic laboratory immunology. 2005;12(6):752-8. DOI: 10.1128/CDLI.12.6.752-758.2005
  29. du Preez K, Seddon JA, Schaaf HS, Hesseling AC, Starke JR, Osman M, et al. Global shortages of BCG vaccine and tuberculous meningitis in children. The Lancet Global health. 2019;7(1):e28-e9. DOI:10.1016/S2214-109X(18)30474-1

Details
Condition Tuberculous Meningitis
Clinical Study IdentifierNCT04308928
SponsorUniversity of Stellenbosch
Last Modified on3 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Children between the ages of 3 months and 13 years with suspected meningitis, and who require CSF examination for routine diagnostic purposes at Tygerberg Children's Hospital
Written informed consent will be obtained from parents for inclusion of children 3 months to 7 years old in the study
If possible, assent will be obtained in those children older than 7 years who have a normal level of consciousness, i.e. a Glasgow Coma Score (GCS) of 15/15

Exclusion Criteria

Children 13 years and older will be excluded from the study
Failure to obtain written consent will also exclude children from the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note